Abstract The role of PET/CT with radiolabelled 18
bloodstream. PSA is thus normally found in the blood in low amounts (nanograms per millilitre). The PSA protein can exist in the blood either free or bound to other substances (complexed PSA). Total PSA is the sum of the free and the bound forms. PSA levels increase in many malignant and benign conditions, such as benign prostatic hyperplasia and prostatitis. Changes in PSA levels over time can be used to assess both cancer risk and aggressiveness of a tumour.
Several parameters have been developed to assess PSA kinetics. Common parameters include the PSA velocity (PSAvel), the rate of change of PSA level over time, defined as the absolute annual increase in serum PSA level (nanograms per millilitre) per year, and the PSA doubling time (PSAdt), defined as the time for the PSA level to double based on an exponential growth pattern. These two measures may have a prognostic role in patients being treated for prostate cancer (PC) [1] .
Prostate cancer
PC shows variable biological behaviour, from a clinically indolent intraprostatic tumour to an aggressive malignancy [1] . In patients with aggressive PC, surgery or radiation therapy (RT), including brachytherapy, external beam RT (EBRT) and intensity modulated RT, are the more commonly used primary treatments. Patients are routinely followed with strict monitoring of PSA levels, and biochemical recurrence occurs in up to 20-30 % of patients [2] . In patients with biochemical relapse, the goal is to distinguish whether disease relapse is localized in the prostate gland or bed or whether metastatic disease is present [2] . Several conventional imaging modalities are currently available, including transrectal ultrasonography (TRUS) with or without biopsy, MR imaging, CT and bone scintigraphy. Each modality has a particular usefulness in imaging certain stages in the natural history of the disease, but all of them have shown limited sensitivity in the detection of the site of relapse after primary treatment [3] [4] [5] [6] [7] .
In this clinical scenario molecular imaging using positron radiopharmaceuticals and PET may play a significant role. In the last few years several radiotracers have been used to visualize PC with PET/CT. The most promising results have been obtained with choline, labelled with either 11 C or 18 F, a substrate for the synthesis of phosphatidylcholine, which is the major phospholipid in the cell membrane [8] .
Choline PET/CT imaging has been proposed for the detection of primary intraprostatic cancer [9] , for staging of the disease [10] and for detection of tumour recurrence in patients with biochemical relapse [11] . This last application is by far the most useful in the clinical setting. This review summarizes the results of the most relevant published studies that have investigated the relationship between PSA, PSA kinetics and choline PET/CT sensitivity. Furthermore, the potential use of PSA kinetics for selection of the patients who will benefit most from this diagnostic procedure, especially early after biochemical recurrence, is discussed.
PSA and PSA kinetics in patients with biochemical recurrence
To date, monitoring PSA serum levels is the best way to follow PC patients after treatment and to detect recurrence of the disease. In patients with biochemical relapse, defined as a PSA >0.2 ng/ml after radical prostatectomy (RP) and as a PSA of 2 ng/ml above the nadir after RT [2] , it is crucial to distinguish between the presence of a single lesion and multiple lesions and to correctly detect the site(s) of relapse in order to establish the proper therapy. As already mentioned, conventional imaging methods have a limited role in the detection of the site(s) of relapse, principally due to their lack of sensitivity when evaluating patients showing low PSA levels [3] [4] [5] [6] [7] .
Accordingly, several studies have focused on the possible relationship between the PC detection rate by 11 C-choline PET/CT and serum PSA levels. Krause et al. [12] evaluated 63 PC patients with biochemical relapse (mean PSA 5.9 ng/ml) after primary treatment with 11 C-choline PET/CT. They demonstrated a significant and strict correlation between the PC detection rate by PET/CT and PSA serum levels: the detection rate was 36 % for PSA <1 ng/ml, 43 % for PSA 1-2 ng/ml, 62 % for PSA 2-3 ng/ml and 73 % for PSA ≥3 ng/ml. The overall PC detection rate by PET/CT was 59 %. Similar results were later confirmed by Giovacchini et al. [13] who evaluated a larger population of 358 PC patients (mean PSA 3.7 ng/ml) by 11 C-choline PET/CT after either RP or RT. These authors found the following percentages of positive 11 C-choline PET/CT findings: 19 % for PSA 0.2-1 ng/ml, 46 % for PSA 1-3 ng/ml, and 82 % for PSA >3 ng/ml. In addition, these authors reported that PSA levels in patients with detectable bone disease were significantly higher than in patients with positive 11 C-choline PET/CT but without bone involvement (p=0.025).
Parameters derived from PSA levels and in particular PSA kinetic parameters (PSAdt and PSAvel) express the change in PSA levels over time. These parameters have emerged as useful predictive markers for assessing disease outcome in patients with PC [2] . In 2009, Castellucci et al. [14] investigated the relationship between the PC detection rate by 11 C-choline PET/CT and other PSA parameters, in particular PSAvel and PSAdt. They enrolled 190 patients with increased PSA levels (mean 4.2 ng/ml) after RP, and demonstrated that PSAdt and PSAvel values were significantly different between patients with PET/CT-positive and PET/CT-negative findings. The detection rate by 11 C-choline PET/CT was 20 % in patients with PSAdt >6 months (n=45), 40 % in patients with PSAdt between 4 and ≤6 months (n=20), 48 % in patients with PSAdt between 2 and ≤4 months (n=31) and 60 % in patients with PSAdt ≤2 months (n=10). Similar results were obtained regarding PSAvel. The authors concluded that PSA kinetics should always be taken into consideration before performing a 11 C-choline PET/CT scan in patients with biochemical relapse, because they were the most relevant factor for a PET/CT-positive result. In 2010, Giovacchini et al. [15] confirmed these findings. They evaluated the influence of PSAdt on the detection rate by 11 C-choline PET/CT in 170 patients after RP with biochemical failure (mean PSA 3.2 ng/ml, median PSAdt 7.0 months). These authors found an overall detection rate of 44 %, as determined by validation 11 C-choline PET/CT findings using criteria based on histological analysis and clinical and imaging data. Multivariate logistic regression showed that a high PSA level and a short PSAdt were the only significant predictors of positive a 11 C-choline PET/CT scan. Moreover, the results of that study demonstrated that PSAdt values differ depending on the site of recurrence: in those with a shorter PSAdt, the presence of a distant metastasis is more probable, while in those with a longer PSAdt the presence of local relapse should be suspected first.
In 2011, Castellucci et al. [16] reported a study evaluating 102 consecutive patients previously treated by RP who showed only a mild increase in PSA serum levels (<1.5 ng/ml, mean 0.86 ± 0.40 ng/ml). Overall, 11 C-choline PET/CT was positive in 29 of 102 patients (28 %). The main finding of this study was that only PSAdt and initial nodal status were found to be significant and independent predictive factors in a multivariate analysis. Mean PSAdt in 11 C-choline PET/CT-positive patients was 4.34 ± 2.82 months, while it was 13.30 ± 9.75 months in 11 C-choline PET/CTnegative patients (p=0.0001). Based on ROC analysis, the optimal threshold for PSAdt was 7.2 months (AUC 0.85, 95 % CI 0.77-0.91) which gave a sensitivity of 93 %, a specificity of 74 %, positive predictive value of 60 %, and a negative predictive value of 96 %.
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C-choline PET/CT was positive in only 2 of 56 patients (3 %) with a PSAdt longer than 7.2 months and was positive in 27 of 46 patients (58 %) with a shorter PSAdt (p=0.001).
In 2012, two interesting studies from the Groningen group were published [17, 18] . Breeuwsma et al. [17] studied 64 patients who underwent 11 C-choline PET/CT for PSA relapse. All patients were initially treated with RP and reached a PSA nadir of <0.1 ng/ml after surgery. The 64 patients had a median PSA of 1.4 ng/ml. The median follow-up period was 50 months (range 6-124 months). No significant differences were seen in age, time to recurrence, initial total PSA level or 11 C-choline PET/CT results. Patients with a positive 11 C-choline PET/CT scan had higher PSAvel values (10.17 ng/ml per year vs. 3.09 ng/ml/year; p=0.002) and shorter PSAdt (0.53 months vs. 4.83 months; p=0.016). In a subsequent larger study by the same group [18] , 185 patients with biochemical relapse after either RP or EBRT were investigated. The majority of the patients (139) had a PSA >3 ng/ml. In a recently published study [19] , 18 F-choline PET/CT was evaluated in 49 patients with rising PSA (mean 4.13 ng/ml). 18 F-Choline PET/CT identified the sites of relapse in 33 of the 49 patients (67 %). 18 F-Choline PET/CT was positive in 7 of 25 patients (84 %) with a PSAdt of ≤6 months, in 12 of 24 patients (50 %) with a PSAdt of >6 months, in 26 of 30 patients (86 %) with a PSAvel >2 ng/ml/year, and in 7 of 19 patients (36.8 %) with a PSAvel ≤2 ng/ml/year.
Graute et al. [20] in a study of PSA kinetics in patients after RP found that 18 F-choline PET/CT detected recurrent lesions in 51 of the 82 patients enrolled (62 %). Their mean PSA level was 4.4 ng/ml. The median PSAvel in PETpositive patients was 6.4 ng/ml/year and in PET-negative patients was 1.1 ng/ml/year (p=0.01). The PSAdt threshold was suggested to be 3.2 months, but this narrowly failed to reach statistical significance (p=0.071).
Discussion
When biochemical relapse is confirmed, options for investigation include biopsy, local (pelvic) imaging and imaging for the presence of metastatic disease [21] . According to recently published guidelines from the European Association of Urology, the use of any diagnostic procedure in patients with biochemical relapse is not be recommended if PSA levels are <20 ng/ml [2] . However, this threshold seems to be appropriate when for whole-body diagnostic studies, such as CT or bone scintigraphy, as they often do not provide valuable information to clinicians in patients with lower PSA levels. As an example, this threshold is different when TRUS is used. Scattoni et al. [22] demonstrated that TRUS is able to accurately detect biopsy-proven local recurrence in patients with a PSA level >2.0 ng/ml. As the detection rate of choline PET/CT surpasses that of standard diagnostic studies and rises with increasing in PSA serum levels, routine use of choline PET/CT has been recommended for those with a PSA level >1 ng/ml [23] . In addition, different clinical and pathological variables have been reported as independent predictors of positive choline PET/CT imaging, and should be considered by clinicians when referring patients for choline PET/CT imaging [14] [15] [16] 23] . In particular, PSAdt has been found to be an important predictor of risk progression after RP or RT [24] . Also, a PSAdt of <3 months has been identified as a useful predictor of PC-specific and overall survival in patients with PC relapse after RP or RT [25] . Conversely, men with a long PSAdt (>15 months) have an extremely low risk of PC-related death. Freedland et al. [26] found that men with a PSAdt longer than 15 months who showed biochemical recurrence more than 3 years after surgery had no PC-related mortality 15 years after the recurrence. The advent of hybrid molecular imaging of PC seems to open a new approach to the use of imaging in patients with biochemical recurrence, making it available and suitable even in patients with very early biochemical relapse. By offering simultaneous assessment of metabolic function and anatomy, hybrid PET/CT has become one of the main imaging tools in clinical oncology. Accurate alignment of both modalities and the use of image fusion have clearly improved diagnostic accuracy and more importantly the confidence and conclusiveness of image interpretation reports compared to the degree of uncertainty that can occur in interpretation of each modality by itself [27] . The accurate and early detection of recurrent disease is crucial to establish a personalized therapeutic approach. In particular, in PC patients, the detection of unexpected distant metastasis may lead to a significant change in therapeutic approach [28] [29] [30] [31] [32] [33] , such as shifting from local RT to systemic treatment or from systemic therapy to PET/CTguided tailored treatments either with surgery or RT [33, 34] . In addition, the recent introduction of integrated whole-body PET/MR imaging has added a promising methodology to clinical practice. The combination of metabolic data from PET with the anatomical and functional information provided by MR imaging may further improve the diagnostic value of each method alone [35] .
It has been reported that the positive detection rate of choline PET/CT imaging depends on PSA plasma levels and PSA kinetics [13] [14] [15] [16] [17] [18] . Its relatively high detection rate in patients with fast PSA kinetics is not surprising: PSA kinetics is, in fact, an expression of prostatic tissue growth and a functional modality, such as choline PET/CT, is thus an appropriate modality for detecting recurrences. None of the known risk factors, including Gleason score and TNM score seems to influence choline PET/CT detection rate as much as PSA kinetics does. Some may argue that results concerning the statistical relevance of both PSAvel and PSAdt are discordant (see Table 1 ). In our opinion the high discrepancies that authors have reported may be mainly attributed to the variety of samples included in the different studies. In particular, the influence of PSAdt is high when the enrolled population has low PSA levels (for example Castellucci et al. [16] whose patients had a PSA serum level of < 1.5 ng/ml with a mean value of 0.8 ng/ml). Conversely, as reported by Graute et al. [20] and Rybalov et al. [18] , PSAdt loses its statistical weight when the PSA serum value is high and/or PSAdt is short. For example, among the large population of 185 patients enrolled by Rybalov et al. [18] were 139 had a PSA level >3 ng/ml, 138 patients had a PSAdt of >6 months, but 125 had a PSAvel of >1 ng/ml/year (Table 1 ). In such populations it is reasonable to expect that either PSA or PSAvel should be the most relevant factors in predicting a positive choline PET/CT scan.
Conclusion
Although final confirmatory data are still needed, preliminary results are encouraging in suggesting that choline PET/CT provides diagnostic information important for therapeutic decision making in patients with recurrent PC [23] [24] [25] [26] . PET/CT with either 11 C-choline or 18 F-choline has shown a significantly higher detection rate of lymphnode or distant metastasis than other imaging modalities, particularly in patients with low PSA values. Such an approach may be particularly useful in younger patients presenting with oligometastatic disease for its ability to provide guidance for localized treatment that could delay the need for systemic hormonal treatment or chemotherapy, thereby reducing toxicity, increasing life quality and delaying resistance to hormonal treatments.
In our opinion choline PET/CT can be recommended as a first-line diagnostic procedure in patients with biochemical relapse showing fast PSA kinetics because (1) a strict correlation between PSA kinetics and choline PET/CT positive findings has been demonstrated, (2) PSA kinetics have been found to be correlated with poor outcome and/or fast progression of disease, and (3) choline PET/CT may guide individually tailored treatment. In particular, based on available literature and our own experience, we consider it appropriate to perform choline PET/CT when the PSAdt is at least less than 6 months and/or the PSAvel is higher than 1 ng/ml/year.
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